Introduction
Prader-Willi syndrome (PWS) was first described in 1956 by Prader, Labhart, and Willi. PWS is a complex genetic disorder caused by the absence of paternally expressed genes on chromosome 15 q11-q13. Current estimates suggest that the incidence of PWS is 1 in 10,000 to 1 in 30,000 live births (Smith & Hung, 2017) . Males and females are affected equally and PWS is found in all races. Newborns with PWS have significant hypotonia, feeding problems, and failure to thrive. Around age two to three years, hyperphagia ensues which can lead to obesity. Children with PWS have developmental and cognitive delay, unique behavior patterns, and neuroendocrine abnormalities. Short stature, characteristic facial features, strabismus, and scoliosis are often present (Miller, 2012) . Hypogonadism manifests as genital hypoplasia, incomplete pubertal development, and almost universal infertility. There is an increased incidence of sleep abnormalities and medical challenges that come with obesity such as type II diabetes mellitus (Driscoll, Miller, Schwartz, & Cassidy, 2016) . Gastrointestinal problems including bowel obstruction, abnormal swallowing, choking, and gastric perforation remain leading causes of morbidity and mortality (Cassidy, Schwartz, Miller, & Driscoll, 2012) . There is no cure for PWS.
The management of PWS requires a multidiscipline approach with emphasis on early diagnosis using accredited genetic testing, early initiation of growth hormone therapy, control of the food environment, exercise and therapies, and consistent interventions for behavior management (Goldstone, Holland, Hauffa, Hokken-Koelega, & Tauber, 2008;  McCandless and the Committee on Genetics, 2011). Nurses are in a unique position to contribute to positive outcomes by pursuing comprehensive care to meet the complex biopsychosocial needs of children with PWS.
Genetics
The critical region for PWS lies within chromosome 15 q11-13. Genomic imprinting is the process by which maternally and paternally derived chromosomes are uniquely chemically modified, leading to different expression of a certain gene or genes on those chromosomes depending on their parental origin (Driscoll et al., 2016) . Normally, the maternally derived copy of chromosome 15, in the region of PWS, is inactivated, or "imprinted", and only the paternally derived portion is expressed (Cassidy et al., 2012) . PWS results when there is an absence of this crucial paternal gene expression.
There are three main genetic subtypes in PWS: paternal deletion, maternal uniparental disomy (UPD), and imprinting defects (ID). Deletions and UPD occur in 70 % and 25% of cases, respectively. ID occurs in less than 5% of cases.
DNA methylation analysis is the only technique that will diagnose all genetic classes of PWS. These mechanisms can occur de novo or as a result of a structural abnormality (Angulo, Butler, & Cataletto, 2015; Smith & Hung, 2017) .
Paternal Deletion: Deletion is the most common cause of PWS (Cassidy et al., 2012) . The absence of the normally active paternal gene results in no active copy of genetic information.
Maternal Uniparental Disomy (UPD): Two maternal copies of the chromosome 15, but no paternal chromosome 15, results in UPD (Smith & Hung, 2017) . Imprinting Defect (ID): The vast majority of cases of PWS are due to sporadic causes, but in some families the defective error can be inherited, including microdeletion (Cassidy et al., 2012) .
Diagnosis
PWS is a well-described clinical dysmorphic syndrome, historically diagnosed by clinical presentation alone. Today, PWS is diagnosed by genetic testing. 99% of cases can be detected using DNA-based methylation testing which detects abnormal parent-specific imprinting within the PWS critical region on chromosome 15 (Smith & Hung, 2017) . DNAbased methylation testing determines whether the region is maternally inherited only (i.e., the normal paternal imprint is absent), but cannot identify the genetic subtype (deletion, UPD, or ID). Once the diagnosis of PWS is established by DNA methylation analysis, determination of the molecular class is the next step. DNA polymorphism analysis should be performed on the proband and parents to distinguish a maternal UPD from an ID. Patients with an ID warrant further investigation. early childhood (Irizarry, Miller, Freemark, & Haqq, 2016) . Neonatal hypotonia is a nearly universal finding which includes: decreased movement, decreased arousal, weak cry, poor reflexes, and a poor suck; often requiring gavage feeding. These findings should prompt genetic testing for PWS while the child is still in the neonatal intensive care unit.
As children grow older, the dysmorphic features of PWS become more prominent: narrow face, almond shaped eyes, thin upper lip, hypopigmented skin and eyes, and strabismus. Behavioral and developmental differences become evident. Early motor milestones are delayed. Most affected individuals test at borderline to mildly low IQ ranges (average IQ of 65), but there is a wide range (Angulo et al., 2015) .
Hypothalamic dysfunction manifests as temperature dysregulation, increased pain tolerance, and central sleep apnea. Endocrine issues include growth hormone deficiency (GHD), hypogonadotropic hypogonadism and less often, central hypothyroidism and central adrenal insufficiency (Irizarry et al., 2016) . Obesity and its complications are the major causes of morbidity and mortality (Cataletto, Angulo, Hertz, & Whitman, 2011) . Insatiable hunger cannot be medically treated only environmentally controlled. With reduced muscle mass, even a lean appearing person with PWS will have a higher fat to muscle ratio with impaired metabolism. Caloric needs of persons with PWS are significantly lower than norms for age or weight.
Individuals with PWS are loving and eager to please. This may lead to creative storytelling to cover up misdeeds. Behavioral challenges include anxiety, stubbornness, compulsive behaviors, rigidity, tantrums, and skin picking. Despite good verbal skills, they are more likely to have speech delays or apraxia (Cassidy et al., 2012) .
Management
Management of PWS is focused on age-dependent anticipatory guidance and addressing the consequences of the syndrome. Prompt diagnosis offers the opportunity to greatly improve health and quality of life in children with PWS.
Specialty care is essential in the management of children with this rare disorder. The team should include experts in genetics, endocrinology, nutrition, behavior, feeding and speech therapy, sleep, and orthopedics. Growth hormone is the only FDA approved medication specifically labeled for children with PWS and should be monitored on a regular basis (Emerick & Vogt, 2013) .
Conclusion
PWS is a complex multisystem genetic disorder which includes endocrinopathies due to hypothalamic dysfunction. It is critical to diagnose PWS early and to provide early interventions. Pediatric nurses are in the ideal position to coordinate care and to provide education and support for families with PWS. The American Academy of Pediatrics has published an excellent comprehensive guide for primary care providers for health supervision of children with PWS (McCandless and the Committee on Genetics, 2011).
Resources for Families and Nurses
Prader-Willi Syndrome Association (USA) www.pwsausa.org. Foundation for Prader-Willi Research www.fpwr.org.
